JP2024526949A5 - - Google Patents
Info
- Publication number
- JP2024526949A5 JP2024526949A5 JP2024503913A JP2024503913A JP2024526949A5 JP 2024526949 A5 JP2024526949 A5 JP 2024526949A5 JP 2024503913 A JP2024503913 A JP 2024503913A JP 2024503913 A JP2024503913 A JP 2024503913A JP 2024526949 A5 JP2024526949 A5 JP 2024526949A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163225407P | 2021-07-23 | 2021-07-23 | |
| US63/225,407 | 2021-07-23 | ||
| US202263329237P | 2022-04-08 | 2022-04-08 | |
| US63/329,237 | 2022-04-08 | ||
| PCT/US2022/037992 WO2023004102A2 (en) | 2021-07-23 | 2022-07-22 | Compositions and methods for inhibition of ras |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024526949A JP2024526949A (ja) | 2024-07-19 |
| JPWO2023004102A5 JPWO2023004102A5 (https=) | 2025-07-30 |
| JP2024526949A5 true JP2024526949A5 (https=) | 2025-07-30 |
Family
ID=82898940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503913A Pending JP2024526949A (ja) | 2021-07-23 | 2022-07-22 | Ｒａｓの阻害のための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20240300964A1 (https=) |
| EP (1) | EP4373822A2 (https=) |
| JP (1) | JP2024526949A (https=) |
| KR (1) | KR20240052096A (https=) |
| AU (1) | AU2022315228A1 (https=) |
| CA (1) | CA3227138A1 (https=) |
| CL (1) | CL2024000201A1 (https=) |
| CO (1) | CO2024000588A2 (https=) |
| IL (1) | IL310291A (https=) |
| MX (1) | MX2024001108A (https=) |
| PE (1) | PE20241063A1 (https=) |
| TW (1) | TW202315610A (https=) |
| WO (1) | WO2023004102A2 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| CN116368130A (zh) | 2020-08-28 | 2023-06-30 | 金橘生物科技公司 | 杂环化合物及其用途 |
| EP4373822A2 (en) | 2021-07-23 | 2024-05-29 | Theras Inc. | Compositions and methods for inhibition of ras |
| TW202334138A (zh) | 2021-11-05 | 2023-09-01 | 美商新領域醫藥公司 | 癌症治療方法 |
| WO2023137223A1 (en) * | 2022-01-17 | 2023-07-20 | Newave Pharmaceutical Inc. | Pan-kras inhibitors and uses thereof |
| WO2023151674A1 (zh) * | 2022-02-14 | 2023-08-17 | 深圳福沃药业有限公司 | 作为kras g12c突变抑制剂的喹唑啉衍生物 |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| KR20240163107A (ko) | 2022-03-11 | 2024-11-18 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
| CN118900838A (zh) * | 2022-03-24 | 2024-11-05 | 百济神州有限公司 | 杂环化合物、其组合物及其治疗方法 |
| AU2023264608A1 (en) * | 2022-05-04 | 2024-11-07 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2023246777A1 (en) * | 2022-06-20 | 2023-12-28 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| CA3261681A1 (en) | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| JP2025525938A (ja) * | 2022-08-05 | 2025-08-07 | セラス， インコーポレイテッド | Ｋｒａｓの阻害のための組成物及び方法 |
| CN120077051A (zh) * | 2022-10-21 | 2025-05-30 | 苏州亚盛药业有限公司 | Kras抑制剂 |
| EP4655298A1 (en) * | 2023-01-24 | 2025-12-03 | Theras Inc. | Compositions and methods for inhibition of ras |
| CN116178284A (zh) * | 2023-02-24 | 2023-05-30 | 重庆医药高等专科学校 | 一种2,4-二羟基喹唑啉及其衍生物的合成方法 |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| CN118834160B (zh) * | 2023-04-23 | 2025-12-19 | 中国医学科学院药物研究所 | Ubrelvy关键手性内酰胺中间体及其衍生物的不对称合成方法 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| CN121605110A (zh) | 2023-06-06 | 2026-03-03 | 金橘生物科技公司 | 取代杂环化合物及其用途 |
| CN119219661A (zh) * | 2023-06-29 | 2024-12-31 | 西藏海思科制药有限公司 | 一种5元杂芳基衍生物及其在医药上的应用 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| WO2025051242A1 (zh) * | 2023-09-08 | 2025-03-13 | 泰励生物科技（上海）有限公司 | Ras抑制剂 |
| AU2024359243A1 (en) * | 2023-10-09 | 2026-04-23 | Incyte Corporation | Processes for preparing kras inhibitors |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025117828A1 (en) * | 2023-12-01 | 2025-06-05 | Theras, Inc. | Compositions and methods for inhibition of ras |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| JP6473133B2 (ja) | 2013-03-15 | 2019-02-20 | アラクセス ファーマ エルエルシー | Ｋｒａｓｇ１２ｃの共有結合性阻害剤 |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| AU2014331794C1 (en) * | 2013-10-10 | 2019-09-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| JP2018513853A (ja) | 2015-04-10 | 2018-05-31 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物およびその使用方法 |
| KR20180081596A (ko) * | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
| AU2018271990A1 (en) * | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| TW202033518A (zh) * | 2018-10-15 | 2020-09-16 | 美商美國禮來大藥廠 | Kras g12c 抑制劑 |
| PT3735299T (pt) | 2018-11-09 | 2024-11-25 | Hoffmann La Roche | Compostos de anéis fundidos |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2020177629A1 (zh) * | 2019-03-01 | 2020-09-10 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物，其制法与医药上的用途 |
| CN112110918B (zh) | 2019-06-21 | 2023-08-22 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物，其制法与医药上的用途 |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CN114929704B (zh) | 2019-12-27 | 2024-07-23 | 微境生物医药科技(上海)有限公司 | 含螺环的喹唑啉化合物 |
| WO2021218110A1 (zh) * | 2020-04-29 | 2021-11-04 | 上海凌达生物医药有限公司 | 一类苯并噻唑基联芳基类化合物、制备方法和用途 |
| CN113754653A (zh) * | 2020-06-05 | 2021-12-07 | 明慧医药（上海）有限公司 | 一种kras g12c抑制剂化合物及其用途 |
| WO2022002102A1 (en) | 2020-06-30 | 2022-01-06 | InventisBio Co., Ltd. | Quinazoline compounds, preparation methods and uses thereof |
| CN113880827B (zh) | 2020-07-03 | 2024-10-01 | 苏州闻天医药科技有限公司 | 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途 |
| CN116368130A (zh) | 2020-08-28 | 2023-06-30 | 金橘生物科技公司 | 杂环化合物及其用途 |
| US20230081426A1 (en) | 2020-09-18 | 2023-03-16 | Plexxikon Inc. | Compounds and methods for kras modulation and indications therefor |
| US20230365563A1 (en) | 2020-09-30 | 2023-11-16 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinazoline compound and application thereof |
| WO2022083616A1 (zh) | 2020-10-21 | 2022-04-28 | 贝达药业股份有限公司 | 一种喹唑啉化合物及其药物组合物 |
| JP2023549055A (ja) | 2020-10-27 | 2023-11-22 | アムジエン・インコーポレーテツド | 複素環式スピロ化合物及びその使用方法 |
| WO2022105855A1 (en) | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| TWI880049B (zh) | 2020-12-04 | 2025-04-11 | 美商美國禮來大藥廠 | Kras g12c抑制劑 |
| CN113999226B (zh) * | 2020-12-22 | 2023-01-06 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| US20240109893A1 (en) | 2020-12-22 | 2024-04-04 | Shanghai Kechow Pharma, Inc. | Preparation and application method of heterocyclic compounds as kras inhibitor |
| US20240140957A1 (en) | 2021-01-08 | 2024-05-02 | Beigene Switzerland Gmbh | Bridged compounds as kras g12d inhibitor and degrader and the use thereof |
| WO2022156792A1 (en) | 2021-01-25 | 2022-07-28 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as sos1 inhibitors |
| AU2022224511A1 (en) * | 2021-02-16 | 2023-08-10 | Lawrence Livermore National Security, Llc | Compositions and methods for inhibition of ras |
| US20240417408A1 (en) | 2021-05-28 | 2024-12-19 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| CN115433179A (zh) | 2021-06-03 | 2022-12-06 | 正大天晴药业集团股份有限公司 | 苯并嘧啶类化合物及其医药用途 |
| CN117500799A (zh) | 2021-06-09 | 2024-02-02 | 伊莱利利公司 | 作为kras g12d抑制剂的取代的稠合吖嗪 |
| EP4373822A2 (en) | 2021-07-23 | 2024-05-29 | Theras Inc. | Compositions and methods for inhibition of ras |
| WO2023018699A1 (en) | 2021-08-10 | 2023-02-16 | Erasca, Inc. | Selective kras inhibitors |
| AR128212A1 (es) | 2022-01-06 | 2024-04-10 | Theras Inc | Composiciones y métodos para la inhibición de ras |
| WO2023133183A1 (en) | 2022-01-06 | 2023-07-13 | Theras, Inc. | Kras inhibitors |
| WO2023141300A1 (en) | 2022-01-20 | 2023-07-27 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| IL314486A (en) | 2022-02-03 | 2024-09-01 | Mirati Therapeutics Inc | Quinazoline compounds inhibit PAN-KRAS |
| CN118900838A (zh) | 2022-03-24 | 2024-11-05 | 百济神州有限公司 | 杂环化合物、其组合物及其治疗方法 |
| AU2023264608A1 (en) | 2022-05-04 | 2024-11-07 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2023225252A1 (en) | 2022-05-20 | 2023-11-23 | Theras, Inc. | Compositions and methods for inhibition of ras |
| WO2024030647A1 (en) | 2022-08-05 | 2024-02-08 | Theras, Inc. | Compositions and methods for inhibition of ras |
| JP2025525938A (ja) | 2022-08-05 | 2025-08-07 | セラス， インコーポレイテッド | Ｋｒａｓの阻害のための組成物及び方法 |
| EP4655298A1 (en) | 2023-01-24 | 2025-12-03 | Theras Inc. | Compositions and methods for inhibition of ras |
| WO2025117828A1 (en) | 2023-12-01 | 2025-06-05 | Theras, Inc. | Compositions and methods for inhibition of ras |
-
2022
- 2022-07-22 EP EP22754656.1A patent/EP4373822A2/en active Pending
- 2022-07-22 PE PE2024000129A patent/PE20241063A1/es unknown
- 2022-07-22 MX MX2024001108A patent/MX2024001108A/es unknown
- 2022-07-22 AU AU2022315228A patent/AU2022315228A1/en active Pending
- 2022-07-22 JP JP2024503913A patent/JP2024526949A/ja active Pending
- 2022-07-22 WO PCT/US2022/037992 patent/WO2023004102A2/en not_active Ceased
- 2022-07-22 IL IL310291A patent/IL310291A/en unknown
- 2022-07-22 US US18/291,432 patent/US20240300964A1/en active Pending
- 2022-07-22 KR KR1020247005781A patent/KR20240052096A/ko active Pending
- 2022-07-22 CA CA3227138A patent/CA3227138A1/en active Pending
- 2022-07-22 TW TW111127590A patent/TW202315610A/zh unknown
-
2024
- 2024-01-23 CL CL2024000201A patent/CL2024000201A1/es unknown
- 2024-01-24 CO CONC2024/0000588A patent/CO2024000588A2/es unknown
-
2025
- 2025-05-01 US US19/196,683 patent/US12528818B2/en active Active